1  5667 105 SFRP TUMOUR SUPPRESSOR GENES ARE POTENTIAL PLASMA-BASED EPIGENETIC BIOMARKERS FOR MALIGNANT PLEURAL MESOTHELIOMA. MALIGNANT PLEURAL MESOTHELIOMA (MPM) IS ASSOCIATED WITH ASBESTOS EXPOSURE. ASBESTOS CAN INDUCE CHRONIC INFLAMMATION WHICH IN TURN CAN LEAD TO SILENCING OF TUMOUR SUPPRESSOR GENES. WNT SIGNALING PATHWAY CAN BE AFFECTED BY CHRONIC INFLAMMATION AND IS ABERRANTLY ACTIVATED IN MANY CANCERS INCLUDING COLON AND MPM. SFRP GENES ARE ANTAGONISTS OF WNT PATHWAY, AND SFRPS ARE POTENTIAL TUMOUR SUPPRESSORS IN COLON, GASTRIC, BREAST, OVARIAN, AND LUNG CANCERS AND MESOTHELIOMA. THIS STUDY INVESTIGATED THE EXPRESSION AND DNA METHYLATION OF SFRP GENES IN MPM CELLS LINES WITH AND WITHOUT DEMETHYLATION TREATMENT. SIXTY-SIX PATIENT FFPE SAMPLES WERE ANALYSED AND HAVE SHOWED METHYLATION OF SFRP2 (56%) AND SFRP5 (70%) IN MPM. SFRP2 AND SFRP5 TUMOUR-SUPPRESSIVE ACTIVITY IN ELEVEN MPM LINES WAS CONFIRMED, AND LONG-TERM ASBESTOS EXPOSURE LED TO REDUCED EXPRESSION OF THE SFRP1 AND SFRP2 GENES IN THE MESOTHELIUM (MET-5A) VIA EPIGENETIC ALTERATIONS. FINALLY, DNA METHYLATION OF SFRPS IS DETECTABLE IN MPM PATIENT PLASMA SAMPLES, WITH METHYLATED SFRP2 AND SFRP5 SHOWING A TENDENCY TOWARDS GREATER ABUNDANCE IN PATIENTS. THESE DATA SUGGESTED THAT SFRP GENES HAVE TUMOUR-SUPPRESIVE ACTIVITY IN MPM AND THAT METHYLATED DNA FROM SFRP GENE PROMOTERS HAS THE POTENTIAL TO SERVE AS A BIOMARKER FOR MPM PATIENT PLASMA.	2017	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
2  1065  32 CLINICAL SIGNIFICANCE OF SERUM DRAM1 MRNA, ARSA MRNA, HSA-MIR-2053 AND LNCRNA-RP1-86D1.3 AXIS EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA. AIM AND BACKGROUND: MALIGNANT PLEURAL MESOTHELIOMA (MPM) IS A LETHAL CANCER MAINLY CAUSED BY CHRONIC EXPOSURE OF ASBESTOS. IN THIS PILOT STUDY, WE AIMED TO ASSESS THE EXPRESSION OF SERUM RNA-BASED BIOMARKER PANEL EXPLORING THEIR CLINICAL UTILITY AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR MPM. METHODS: WE HAVE SELECTED AN MPM-SPECIFIC RNA-BASED BIOMARKER PANEL THROUGH BIOINFORMATICS ANALYSIS BASED ON THE INTEGRATION OF DNA DAMAGE REGULATED AUTOPHAGY MODULATOR 1 (DRAM1) AND ARYLSULFATASE A ( ARSA) GENE EXPRESSION WITH THEIR EPIGENETIC REGULATORS MICRORNA ( MIR-2053) AND LONG NONCODING RNA ( LNCRNA-RP1-86D1.3). THEN, QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QPCR) VALIDATION IN SERA OF 60 MPM PATIENTS, 20 CHRONIC ASBESTOS EXPOSURE PATIENTS, AND 20 HEALTHY VOLUNTEERS WAS DONE. LASTLY, THE PROGNOSTIC POWER OF THE SELECTED PANEL WAS ASSESSED. RESULTS: THE EXPRESSION OF SERUM DRAM1 MESSENGER RNA (MRNA), ARSA MRNA, HSA-MIR-2053 AND LNCRNA-RP1-86D1.3 WERE POSITIVE IN 78.3%, 90%, 85%, AND 83.3% OF MPM PATIENTS, RESPECTIVELY. THE RNA-BASED BIOMARKER PANEL WAS ABLE TO DISCRIMINATE BETWEEN MPM PATIENTS AND CONTROLS WITH HIGH ACCURACY AND THEIR COMBINED SENSITIVITY REACHED 100% FOR THE DIAGNOSIS OF MPM. KAPLAN-MEIER ANALYSIS SHOWED THAT HSA-MIR-2053 IS AN INDEPENDENT PROGNOSTIC FACTOR OF MPM. CONCLUSION: OUR PRELIMINARY DATA REVEALED THAT THE CHOSEN RNAS PLAY AN IMPORTANT ROLE IN DRIVING MPM DEVELOPMENT AND PROGRESSION.	2019	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
3  4201  33 METABOLIC REWIRING AND REDOX ALTERATIONS IN MALIGNANT PLEURAL MESOTHELIOMA. MALIGNANT PLEURAL MESOTHELIOMA (MPM) IS A RARE MALIGNANCY OF MESOTHELIAL CELLS WITH INCREASING INCIDENCE, AND IN MANY CASES, DISMAL PROGNOSIS DUE TO ITS AGGRESSIVENESS AND LACK OF EFFECTIVE THERAPIES. ENVIRONMENTAL AND OCCUPATIONAL EXPOSURE TO ASBESTOS IS CONSIDERED THE MAIN AETIOLOGICAL FACTOR FOR MPM. INHALED ASBESTOS FIBRES ACCUMULATE IN THE LUNGS AND INDUCE THE GENERATION OF REACTIVE OXYGEN SPECIES (ROS) DUE TO THE PRESENCE OF IRON ASSOCIATED WITH THE FIBROUS SILICATES AND TO THE ACTIVATION OF MACROPHAGES AND INFLAMMATION. CHRONIC INFLAMMATION AND A ROS-ENRICHED MICROENVIRONMENT CAN FOSTER THE MALIGNANT TRANSFORMATION OF MESOTHELIAL CELLS. IN ADDITION, MPM CELLS HAVE A HIGHLY GLYCOLYTIC METABOLIC PROFILE AND ARE POSITIVE IN (18)F-FDG PET ANALYSIS. LOSS-OF-FUNCTION MUTATIONS OF BRCA-ASSOCIATED PROTEIN 1 (BAP1) ARE A MAJOR CONTRIBUTOR TO THE METABOLIC REWIRING OF MPM CELLS. A SUBSET OF MPM TUMOURS SHOW LOSS OF THE METHYLADENOSINE PHOSPHORYLASE (MTAP) LOCUS, RESULTING IN PROFOUND ALTERATIONS IN POLYAMINE METABOLISM, ATP AND METHIONINE SALVAGE PATHWAYS, AS WELL AS CHANGES IN EPIGENETIC CONTROL OF GENE EXPRESSION. THIS REVIEW PROVIDES AN OVERVIEW OF THE PERTURBATIONS IN METABOLISM AND ROS HOMOEOSTASIS OF MPM CELLS AND THE ROLE OF THESE ALTERATIONS IN MALIGNANT TRANSFORMATION AND TUMOUR PROGRESSION.	2020	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
4  1484  32 DLEU2: A MEANINGFUL LONG NONCODING RNA IN ONCOGENESIS. BACKGROUND: LONG NON-CODING RNA (LNCRNA) WITH LITTLE OR NO CODING ABILITY HAS SHOWN A VARIETY OF BIOLOGICAL FUNCTIONS IN CANCER, INCLUDING EPIGENETIC REGULATION, DNA DAMAGE, REGULATION OF MICRORNAS, AND PARTICIPATION IN SIGNAL TRANSDUCTION PATHWAYS. LNCRNA CAN BE USED AS AN ONCOGENE AND TUMOR SUPPRESSOR GENE THROUGH TRANSCRIPTIONAL REGULATION IN CANCER. FOR EXAMPLE, THE OVER-EXPRESSED LNCRNA DLEU2 PROMOTES THE OCCURRENCE OF LARYNGEAL CANCER, LUNG CANCER, HEPATOCELLULAR CARCINOMA, ETC., AND INHIBITS THE PROGRESSION OF CHRONIC LYMPHOCYTIC LEUKEMIA. DELETED IN LYMPHOCYTIC LEUKEMIA 2 (DLEU2), AS ONE OF THE LONG NON-CODING RNAS, WAS FIRST FOUND IN CHRONIC LYMPHOBLASTIC LEUKEMIA AND DRAWN INTO THE PROGRESS OF INNUMERABLE CANCERS. THE MOLECULAR MECHANISM OF DLEU2 IN MULTIPLE TUMORS WILL BE REVEALED. METHODS: IN THIS REVIEW, CURRENT STUDIES ON THE BIOLOGICAL FUNCTIONS AND MECHANISMS OF DLEU2 IN TUMORS ARE SUMMARIZED AND ANALYZED; RELATED RESEARCHES ARE SYSTEMATICALLY RETRIEVED AND COLLECTED THROUGH PUBMED. RESULTS: DLEU2, A NOVEL CANCER-RELATED LNCRNA, HAS BEEN DEMONSTRATED TO BE ABNORMALLY EXPRESSED IN VARIOUS MALIGNANT TUMORS, INCLUDING LEUKEMIA, ESOPHAGEAL CANCER, LUNG CANCER, GLIOMA, HEPATOCELLULAR CARCINOMA, MALIGNANT PLEURAL MESOTHELIOMA, BLADDER CANCER, PANCREATIC CANCER, PHARYNX AND THROAT CANCER, RENAL CLEAR CELL CARCINOMA, BREAST CANCER, OSTEOSARCOMA. BESIDES, LNCRNA DLEU2 HAS BEEN SHOWN TO BE INVOLVED IN THE PROCESS OF PROLIFERATION, MIGRATION, INVASION AND INHIBITION OF APOPTOSIS OF CANCER CELLS. CONCLUSION: DUE TO THE BIOLOGICAL FUNCTIONS AND MECHANISMS INVOLVED IN DLEU2, IT MAY REPRESENT AN AVAILABLE BIOMARKER OR POTENTIAL THERAPEUTIC TARGET IN A VARIETY OF MALIGNANT TUMORS.	2021	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
5   386  31 AN IN VIVO IMMUNOHISTOCHEMICAL STUDY ON MACROH2A.1 IN LUNG AND LYMPH-NODE TISSUES EXPOSED TO AN ASBESTIFORM FIBER. AIMS: THE AIM OF THIS STUDY WAS TO INVESTIGATE MACROH2A.1 IMMUNOEXPRESSION IN TISSUES OF SHEEP EXPOSED TO FE. BACKGROUND: THE CORRELATION BETWEEN ASBESTIFORM FIBERS, LUNG CANCER, PLEURAL MESOTHELIOMA, AND OTHER LUNG DISEASES IS ALREADY WELL ESTABLISHED AS THE PATHOPHISIOLOGICAL PATHOPHYSIOLOGICAL RESPIRATORY MECHANISMS INVOLVED BY INHALATION OF FLUORO-EDENITE (FE). THE LATTER IS REPRESENTED BY CELL PROLIFERATION AND INDUCING THE RELEASE OF GROWTH FACTORS, CYTOKINES, AND REACTIVE OXYGEN AND NITRITE SPECIES, WITH DNA DAMAGE THAT CAUSES CHRONIC INFLAMMATION AND CARCINOGENESIS. MACROH2A.1, AND HISTONE VARIANT, SEEMS TO PLAY A ROLE IN SENSING THE METABOLIC STATE OF THE CELL AND LINKING IT WITH CHROMATIN. PHYSIOLOGICALLY, MACROH2A.1 IS EXPRESSED AT LOW LEVELS IN STEM CELLS AND IT BECAME UPREGULATED DURING DIFFERENTIATION, PREVENTING REPROGRAMMING OF INDUCED PLURIPOTENT STEM CELLS AND AFTER NUCLEAR TRANSFER. IN PARTICULAR, MACROH2A.1 HAS BEEN SHOWN TO EXPLICATE A POTENT ANTITUMOR MECHANISM IN VIVO AS IT RESULTS UPREGULATED IN SENESCENT CELLS DETERMINING A PERMANENT GROWTH-ARREST. OBJECTIVE: EVALUATE THE POSSIBLE ROLE OF THE HISTONE VARIANT IN THE ORGANISM IN RESPONSE TO DEEP INSIGHT UNDERSTANDING THE MECHANISMS OF TOXICITY AND THE CELLULAR RESPONSE TO FE. METHODS: LUNG AND LYMPH NODES OF EXPOSED SHEEP WERE SELECTED. SAMPLES WERE PROCESSED FOR HISTOLOGICAL AND IMMUNIHISTOCHEMICAL IMMUNOHISTOCHEMICAL EVALUATIONS. DENSITOMETRIC, MORPHOMETRIC, AND STATISTICAL ANALYSIS ANALYSES WERE CONDUCTED. RESULTS: TISSUE SECTIONS OF FE EXPOSED SHEEP DEMONSTRATED OVEREXPRESSION OF MACROH2A.1 VS UNEXPOSED SAMPLES. THE DATA SUGGEST AN INVOLVEMENT OF THESE THIS MOLECULE IN THE CELLULAR RESPONSE TRIGGERED BY FE DIRECTED EXPOSURE. CONCLUSION: IN THIS CONTEST, MACROH2A.1 OVEREXPRESSION SUPPORTS ITS FUNCTION AS AN EPIGENETIC STABILIZER THAT HELPS TO ESTABLISH AND MAINTAIN DIFFERENTIATED STATES.	2020	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
6  5144  29 POTENTIAL ROLE OF LNCRNA-TSIX, MIR-548-A-3P, AND SOGA1 MRNA IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA. RECENT TRENDS ARE MOVING TOWARDS THE USE OF THE CIRCULATING TRANSCRIPTOME AS A POTENTIAL DIAGNOSTIC AND THERAPEUTIC TOOL FOR HEPATOCELLULAR CARCINOMA (HCC). THE AIM OF THIS STUDY IS TO IDENTIFY CIRCULATORY RNA BASED BIOMARKER PANEL, IN ADDITION TO THEIR RELATIONSHIP TO THE OUTCOME IN HCC. FIRST, UTILIZING BIOINFORMATICS TOOLS, WE SELECTED AN HCC-SPECIFIC RNA-BASED BIOMARKER PANEL THAT DEPENDED ON THE INTEGRATION OF SUPPRESSOR OF GLUCOSE AUTOPHAGY-ASSOCIATED (SOGA1) GENE EXPRESSION WITH THE CHOSEN PANEL OF EPIGENETIC REGULATORS OF THIS GENE [LONG NON-CODING RNA ANTISENSE FOR X-INACTIVE-SPECIFIC TRANSCRIPT (LNCRNA-TSIX) AND MICRORNA-548-A-3P (MIR-548-A-3P)]. SECOND, WE ATTEMPTED TO VALIDATE THESE BIOMARKERS USING THE SERA OF 65 PATIENTS WITH HCC, 34 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (CHC) INFECTION AND 32 HEALTHY VOLUNTEERS. FINALLY, THE EXPRESSION LEVELS OF THE CHOSEN RNA-BASED BIOMARKER PANEL WERE ASSESSED IN THE SERUM SAMPLES USING QRT-PCR ASSAYS. THE PANEL OF 3 RNA-BASED BIOMARKERS (LNCRNA-TSIX, MIR-548-A-3P, AND SOGA1) EXHIBITED HIGH SENSITIVITY AND SPECIFICITY IN DIFFERENTIATING HCC PATIENTS FROM CHC PATIENTS AND HEALTHY CONTROLS. AMONG THESE 3 RNAS, SERUM LNCRNA-TSIX AND SOGA1 WERE INDEPENDENT PROGNOSTIC FACTOR. THE CHOSEN CIRCULATORY RNA-BASED BIOMARKER PANEL MAY SERVE AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER FOR HCC.	2019	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
7  2426  30 EPIGENETIC SILENCING OF LONG NON-CODING RNA BM742401 IN MULTIPLE MYELOMA: IMPACT ON PROGNOSIS AND MYELOMA DISSEMINATION. BACKGROUND: LONG NON-CODING RNA (LNCRNA) BM742401 IS A TUMOR SUPPRESSOR IN GASTRIC CANCER AND CHRONIC LYMPHOCYTIC LEUKEMIA. AS THE PROMOTER AND CODING REGION OF BM742401 ARE FULLY EMBEDDED IN A CPG ISLAND, WE HYPOTHESIZED THAT BM742401 IS A TUMOR SUPPRESSOR LNCRNA EPIGENETICALLY SILENCED BY PROMOTER DNA METHYLATION IN MULTIPLE MYELOMA. METHODS: METHYLATION-SPECIFIC PCR AND QUANTITATIVE BISULFITE PYROSEQUENCING WERE PERFORMED TO DETECT THE METHYLATION OF BM742401 IN NORMAL PLASMA CELLS, MYELOMA CELL LINES AND PRIMARY MYELOMA SAMPLES. THE EXPRESSION OF BM742401 WAS MEASURED BY QRT-PCR. THE FUNCTION OF BM742401 IN MULTIPLE MYELOMA CELLS WAS ANALYZED BY LENTIVIRUS TRANSDUCTION FOLLOWED BY MIGRATION ASSAY. RESULTS: BM742401 METHYLATION WAS DETECTED IN 10 (66.7%) MYELOMA CELL LINES BUT NOT NORMAL PLASMA CELLS, AND INVERSELY CORRELATED WITH EXPRESSION OF BM742401. IN PRIMARY SAMPLES, BM742401 METHYLATION WAS DETECTED IN 3 (12.5%) MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE, 9 (15.8%) MYELOMA AT DIAGNOSIS AND 8 (17.0%) MYELOMA AT RELAPSE/PROGRESSION. MOREOVER, BM742401 METHYLATION AT DIAGNOSIS WAS ASSOCIATED WITH INFERIOR OVERALL SURVIVAL (MEDIAN OS: 25 VS. 39 MONTHS; P = 0.0496). IN MYELOMA CELL LINE JJN-3, STABLE OVEREXPRESSION OF BM742401 BY LENTIVIRUS TRANSDUCTION RESULTED IN REDUCED CELL MIGRATION (P = 0.0001) BUT NOT IMPACTING CELL DEATH OR PROLIFERATION. CONCLUSIONS: THIS IS THE FIRST REPORT OF TUMOR-SPECIFIC METHYLATION-MEDIATED SILENCING OF BM742401 IN MYELOMA, WHICH IS LIKELY AN EARLY EVENT IN MYELOMAGENESIS WITH ADVERSE IMPACT ON OVERALL SURVIVAL. MOREOVER, BM742401 IS A TUMOR SUPPRESSOR LNCRNA BY INHIBITING MYELOMA CELL MIGRATION, HENCE IMPLICATED IN MYELOMA PLASMA CELL HOMING, METASTASIS AND DISEASE PROGRESSION.	2020	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
8  2844  31 FREQUENT EPIGENETIC INACTIVATION OF SFRP GENES IN HEPATOCELLULAR CARCINOMA. BACKGROUND: ACTIVATION OF THE WNT SIGNALING PATHWAY IS FREQUENTLY OBSERVED IN HEPATOCELLULAR CARCINOMA (HCC), THOUGH MUTATION OF THREE OF ITS COMPONENTS, CTNNB1, AXIN1, AND AXIN2, IS OBSERVED SUBSTANTIALLY LESS OFTEN. METHODS: WE EXAMINED THE RELATIONSHIP BETWEEN WNT SIGNALING AND EPIGENETIC ALTERATION OF SECRETED FRIZZLED-RELATED PROTEIN (SFRP) GENES IN HCC. RESULTS: WE FREQUENTLY DETECTED THE ACTIVE FORM OF BETA-CATENIN AND ACCUMULATION OF NUCLEAR BETA-CATENIN IN LIVER CANCER CELL LINES. WE DETECTED METHYLATION OF SFRP FAMILY GENES IN LIVER CANCER CELL LINES (SFRP1, 9/12, 75%; SFRP2, 7/12, 58%; SFRP4, 3/12, 25%; SFRP5, 7/12, 58%) AND PRIMARY HCCS (SFRP1, 9/19, 47%; SFRP2, 12/19, 63%; SFRP5, 8/19, 42%), THOUGH METHYLATION OF SFRP4 WAS NOT FOUND IN PRIMARY HCCS. SFRP METHYLATION ALSO WAS DETECTED IN HEPATITIS B OR C VIRUS-ASSOCIATED CHRONIC HEPATITIS (SFRP1, 6/37, 16%; SFRP2, 14/37, 38%; SFRP5, 5/37, 14%) AND LIVER CIRRHOSIS (SFRP1, 10/28, 36%; SFRP2, 9/28, 32%; SFRP5, 3/28, 11%), SUGGESTING THAT METHYLATION OF THESE GENES IS AN EARLY EVENT IN LIVER CARCINOGENESIS. ECTOPIC EXPRESSION OF SFRPS DOWNREGULATED T-CELL FACTOR/LYMPHOCYTE ENHANCER FACTOR (TCF/LEF) TRANSCRIPTIONAL ACTIVITY IN LIVER CANCER CELLS, WHILE OVEREXPRESSION OF A BETA-CATENIN MUTANT AND DEPLETION OF SFRP1 USING SIRNA SYNERGISTICALLY UPREGULATED TCF/LEF TRANSCRIPTIONAL ACTIVITY. CONCLUSIONS: OUR RESULTS CONFIRM THE FREQUENT METHYLATION AND SILENCING OF WNT ANTAGONIST GENES IN HCC, AND SUGGEST THAT THEIR LOSS OF FUNCTION CONTRIBUTES TO ACTIVATION OF WNT SIGNALING DURING HEPATOCARCINOGENESIS.	2008	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
9  2786  23 EZH2 RESTRICTS THE SMOOTH MUSCLE LINEAGE DURING MOUSE LUNG MESOTHELIAL DEVELOPMENT. DURING DEVELOPMENT, THE LUNG MESODERM GENERATES A VARIETY OF CELL LINEAGES, INCLUDING AIRWAY AND VASCULAR SMOOTH MUSCLE. EPIGENETIC CHANGES IN ADULT LUNG MESODERMAL LINEAGES ARE THOUGHT TO CONTRIBUTE TOWARDS DISEASES SUCH AS IDIOPATHIC PULMONARY FIBROSIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ALTHOUGH THE FACTORS THAT REGULATE EARLY LUNG MESODERM DEVELOPMENT ARE UNKNOWN. WE SHOW IN MOUSE THAT THE PRC2 COMPONENT EZH2 IS REQUIRED TO RESTRICT SMOOTH MUSCLE DIFFERENTIATION IN THE DEVELOPING LUNG MESOTHELIUM. MESODERMAL LOSS OF EZH2 LEADS TO THE FORMATION OF ECTOPIC SMOOTH MUSCLE IN THE SUBMESOTHELIAL REGION OF THE DEVELOPING LUNG MESODERM. LOSS OF EZH2 SPECIFICALLY IN THE DEVELOPING MESOTHELIUM REVEALS A MESOTHELIAL CELL-AUTONOMOUS ROLE FOR EZH2 IN REPRESSION OF THE SMOOTH MUSCLE DIFFERENTIATION PROGRAM. LOSS OF EZH2 DEREPRESSES EXPRESSION OF MYOCARDIN AND TBX18, WHICH ARE IMPORTANT REGULATORS OF SMOOTH MUSCLE DIFFERENTIATION FROM THE MESOTHELIUM AND RELATED CELL LINEAGES. TOGETHER, THESE FINDINGS UNCOVER AN EZH2-DEPENDENT MECHANISM TO RESTRICT THE SMOOTH MUSCLE GENE EXPRESSION PROGRAM IN THE DEVELOPING MESOTHELIUM AND ALLOW APPROPRIATE CELL FATE DECISIONS TO OCCUR IN THIS MULTIPOTENT MESODERM LINEAGE.	2016	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
10  3413  35 HSA-MIR-29C AND HSA-MIR-135B DIFFERENTIAL EXPRESSION AS POTENTIAL BIOMARKER OF GASTRIC CARCINOGENESIS. AIM: TO INVESTIGATE THE EXPRESSION PROFILES OF HSA-MIR-29C AND HSA-MIR-135B IN GASTRIC MUCOSAL SAMPLES AND THEIR VALUES AS GASTRIC CARCINOGENESIS BIOMARKERS. METHODS: THE EXPRESSION LEVELS OF HSA-MIR-29C AND HSA-MIR-135B IN NORMAL GASTRIC MUCOSA, NON-ATROPHIC CHRONIC GASTRITIS, INTESTINAL METAPLASIA AND INTESTINAL-TYPE GASTRIC ADENOCARCINOMA WERE ANALYSED USING QUANTITATIVE REAL-TIME PCR. THE DIFFERENCE BETWEEN HSA-MIR-29C AND HSA-MIR-135B EXPRESSION PROFILES IN THE GROUPED SAMPLES WAS EVALUATED BY ANOVA AND STUDENT'S T-TEST TESTS. THE RESULTS WERE ADJUSTED FOR MULTIPLE TESTING BY USING BONFERRONI'S CORRECTION. P VALUES </= 0.05 WERE CONSIDERED STATISTICALLY SIGNIFICANT. TO EVALUATE HSA-MIR-29C AND HSA-MIR-135B EXPRESSIONS AS POTENTIAL BIOMARKERS OF GASTRIC CARCINOGENESIS, WE PERFORMED A RECEIVER OPERATING CHARACTERISTIC CURVE ANALYSIS AND THE DERIVED AREA UNDER THE CURVE, AND A CATEGORICAL PRINCIPAL COMPONENTS ANALYSIS. IN SILICO IDENTIFICATION OF THE GENETIC TARGETS OF HSA-MIR-29C AND HSA-MIR-135B WAS PERFORMED USING DIFFERENT PREDICTION TOOLS, IN ORDER TO IDENTIFY POSSIBLE GENES INVOLVED IN GASTRIC CARCINOGENESIS. RESULTS: THE EXPRESSION LEVELS OF HSA-MIR-29C WERE HIGHER IN NORMAL GASTRIC MUCOSAL SAMPLES, AND DECREASED PROGRESSIVELY IN NON-ATROPHIC CHRONIC GASTRITIS SAMPLES, INTESTINAL METAPLASIA SAMPLES AND INTESTINAL-TYPE GASTRIC ADENOCARCINOMA SAMPLES. THE EXPRESSION OF HSA-MIR-29C IN THE GASTRIC LESIONS SHOWED THAT NON-ATROPHIC GASTRITIS HAVE AN INTERMEDIATE PROFILE TO GASTRIC NORMAL MUCOSA AND INTESTINAL-TYPE GASTRIC ADENOCARCINOMA, AND THAT INTESTINAL METAPLASIA SAMPLES PRESENTED AN EXPRESSION PATTERN SIMILAR TO THAT IN INTESTINAL-TYPE GASTRIC ADENOCARCINOMA. THIS MICRORNA (MIRNA) HAS A GOOD DISCRIMINATORY ACCURACY BETWEEN NORMAL GASTRIC SAMPLES AND (1) INTESTINAL-TYPE GASTRIC ADENOCARCINOMA; AND (2) INTESTINAL METAPLASIA, AND REGULATES THE DMNT3A ONCOGENE. HSA-MIR-135B IS UP-REGULATED IN NON-ATROPHIC CHRONIC GASTRITIS AND INTESTINAL METAPLASIA SAMPLES AND DOWN-REGULATED IN NORMAL GASTRIC MUCOSA AND INTESTINAL-TYPE GASTRIC ADENOCARCINOMA SAMPLES. NON-ATROPHIC CHRONIC GASTRITIS AND INTESTINAL METAPLASIA ARE SIGNIFICANTLY DIFFERENT FROM NORMAL GASTRIC MUCOSA SAMPLES. HSA-MIR-135B EXPRESSION PRESENTED A GREATER DISCRIMINATORY ACCURACY BETWEEN NORMAL SAMPLES AND GASTRIC LESIONS. THIS MIRNA WAS ASSOCIATED WITH HELICOBACTER PYLORI PRESENCE IN NON-ATROPHIC CHRONIC GASTRITIS SAMPLES AND REGULATES THE APC AND KLF4 TUMOUR SUPPRESSOR GENES. CONCLUSION: OUR RESULTS PROVIDE EVIDENCE OF EPIGENETIC ALTERATIONS IN NON-ATROPHIC CHRONIC GASTRITIS AND INTESTINAL METAPLASIA AND SUGGEST THAT HSA-MIR-29C AND HSA-MIR-135B ARE PROMISING BIOMARKERS OF GASTRIC CARCINOGENESIS.	2016	

11  2131  32 EPIGENETIC INACTIVATION OF THE HSA-MIR-203 IN HAEMATOLOGICAL MALIGNANCIES. MIR-203 IS A TUMOUR SUPPRESSOR MICRORNA (MIRNA). WE STUDIED THE METHYLATION OF HSA-MIR-203 IN 150 SAMPLES INCLUDING ACUTE MYELOID LEUKAEMIA (AML), ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL), CHRONIC MYELOID LEUKAEMIA (CML), CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) AND NON-HODGKIN'S LYMPHOMA (NHL) BY METHYLATION-SPECIFIC PCR, AND MIRNA EXPRESSION BY STEM-LOOP RT-QPCR. HSA-MIR-203 PROMOTER WAS UNMETHYLATED IN NORMAL CONTROLS BUT HOMOZYGOUSLY METHYLATED IN TWO AML AND FOUR LYMPHOMA CELL LINES, IN WHICH 5-AZA-2'-DEOXYCYTIDINE TREATMENT LED TO PROMOTER DEMETHYLATION AND MIR-203 RE-EXPRESSION. RESTORATION OF MIR-203 EXPRESSION IN LYMPHOMA CELLS INHIBITED CELLULAR PROLIFERATION AND INCREASED CELL DEATH, SUGGESTING AN INHERENT TUMOUR SUPPRESSOR ACTIVITY. IN PRIMARY SAMPLES, HSA-MIR-203 METHYLATION WAS ABSENT IN CML BUT DETECTED IN 5.0% ALL, 10.0% AML, 42.0% CLL AND 38.8% OF NHL (INCLUDING SIX [60.0%] NATURAL KILLER-CELL, NINE [40.9%] B-CELL AND FOUR [23.5%] T CELL NHL). MOREOVER, HSA-MIR-203 METHYLATION WAS ASSOCIATED WITH HYPERMETHYLATION OF HSA-MIR-34A, -124A AND -196B IN NHL BUT NOT CLL. IN CLL, HSA-MIR-203 METHYLATION WAS ASSOCIATED WITH A HIGHER PRESENTING HB LEVEL (P = 0.033). THE PROJECTED 10 YEAR OVERALL SURVIVAL OF THE CLL PATIENTS WAS 58.2%, WHICH WAS IMPACTED BY RAI STAGE AND HIGH-RISK KARYOTYPES BUT NOT HSA-MIR-203 METHYLATION. HSA-MIR-203 WAS MORE FREQUENTLY METHYLATED IN LYMPHOID THAN MYELOID MALIGNANCIES (P = 0.002). IN CONCLUSION, MIR-203, A TUMOUR SUPPRESSOR GENE, WAS HYPERMETHYLATED IN A TUMOUR-SPECIFIC MANNER WITH GENE SILENCING. HSA-MIR-203 WAS MORE FREQUENTLY HYPERMETHYLATED IN LYMPHOID THAN MYELOID MALIGNANCIES. IN NHL, HSA-MIR-203 METHYLATION WAS ASSOCIATED WITH CONCOMITANT METHYLATION OF OTHER TUMOUR SUPPRESSOR MIRNAS. THE FREQUENT HSA-MIR-203 METHYLATION IN LYMPHOID MALIGNANCIES SUGGESTED A PATHOGENETIC ROLE OF HSA-MIR-203 METHYLATION.	2011	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
12  2679  26 EVALUATION OF CIRCULATORY RNA-BASED BIOMARKER PANEL IN HEPATOCELLULAR CARCINOMA. BACKGROUND: THE CIRCULATING TRANSCRIPTOME (CODING AND NON-CODING) PLAYS A CRITICAL ROLE IN CANCER. NOVEL ACCURATE STRATEGIES FOR EARLY DETECTION OF HEPATOCELLULAR CARCINOMA (HCC) ARE STRONGLY NEEDED. PATIENTS AND METHODS: WE CHOSE AN HCC-SPECIFIC RNA-BASED BIOMARKER PANEL BASED ON THE INTEGRATION OF DIFFERENTIAL LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2 (LAMP2) GENE EXPRESSION WITH ITS SELECTED EPIGENETIC REGULATORS USING BIOINFORMATIC METHODS. THIS WAS FOLLOWED BY RT-QPCR VALIDATION IN SERUM OF 78 PATIENTS WITH HCC, 36 PATIENTS WITH CHRONIC HEPATITIS C (CHC) INFECTION AND 44 HEALTHY VOLUNTEERS. WE USED RISK-SCORE ANALYSIS TO EVALUATE THE DIAGNOSTIC EFFICACY OF THE SERUM PROFILING SYSTEM. MOREOVER, IN TWENTY OF THE 78 HCC CASES INVOLVED IN THE STUDY WE EXAMINED THE EXPRESSION OF RNA-BASED BIOMARKER PANEL IN BOTH HCC AND ADJACENT NON-TUMOR TISSUES AND ASSESSED THEIR CORRELATION WITH THE SERUM LEVEL OF THIS PANEL. RESULTS: THE FOUR RIBONUCLEIC ACID (RNA)-BASED BIOMARKER PANEL [LONG NON-CODING RNA-C TERMINAL BINDING PROTEIN, ANDROGEN RESPONSIVE (LNCRNA-CTBP), MICRORNA-16-2 (MIR-16-2), MICRORNA-21-5-P (MIR-21-5P) AND LAMP2], HAD HIGH SENSITIVITY AND SPECIFICITY FOR DISCRIMINATING HCC FROM HEALTHY CONTROLS AND ALSO FROM CHC PATIENTS. AMONG THESE FOUR RNAS, SERUM MIR-16-2 AND MIR-21-5P WERE INDEPENDENT PROGNOSTIC FACTORS. CONCLUSION: THE CIRCULATORY RNA-BASED BIOMARKER PANEL CAN SERVE AS A POTENTIAL BIOMARKER FOR HCC DIAGNOSIS AND PROGNOSIS.	2016	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
13  4260  25 METTL3-MEDIATED M6A MODIFICATION OF SIRT1 MRNA INHIBITS PROGRESSION OF ENDOMETRIOSIS BY CELLULAR SENESCENCE ENHANCING. BACKGROUND: ENDOMETRIOSIS (EMS), THE ECTOPIC PLANTING OF FUNCTIONAL ENDOMETRIUM OUTSIDE OF THE UTERUS, IS A LEADING CAUSE OF INFERTILITY AND PELVIC PAIN. AS A FUNDAMENTAL MRNA MODIFICATION, N6-METHYLADENOSINE (M6A) PARTICIPATES IN VARIOUS PATHOLOGICAL PROCESSES. HOWEVER, THE ROLE OF M6A RNA MODIFICATION IN ENDOMETRIOSIS REMAINS UNCLEAR. THE PRESENT STUDY EXPLORES METTL3-MEDIATED M6A MODIFICATION AND THE MECHANISMS INVOLVED IN ENDOMETRIOSIS. METHODS: THE DOMINANT M6A REGULATORS IN EMS WERE ANALYSED USING RT?PCR. CANDIDATE TARGETS AND POSSIBLE MECHANISMS OF METTL3 WERE ASSESSED BY M6A-MRNA EPITRANSCRIPTOMIC MICROARRAY AND RNA SEQUENCING. A PRIMARY ESCS MODEL WAS EMPLOYED TO VERIFY THE EFFECT OF METTL3 ON M6A MODIFICATION OF SIRT1 MRNA, AND THE MECHANISM WAS ELUCIDATED BY RT?PCR, WESTERN BLOTTING, MERIP, AND RIP ASSAYS. CCK-8 VIABILITY ASSAYS, TRANSWELL INVASION ASSAYS, EDU PROLIFERATION ASSAYS, WOUND HEALING MIGRATION ASSAYS, AND SENESCENCE-ASSOCIATED BETA-GALACTOSIDASE STAINING WERE PERFORMED TO ILLUMINATE THE POTENTIAL BIOLOGICAL MECHANISM OF METTL3 AND SIRT1 IN ESCS IN VITRO. AN IN VIVO PGRCRE/ + METTL3 -/- FEMALE HOMOZYGOUS MOUSE MODEL AND A NUDE MOUSE XENOGRAFT MODEL WERE EMPLOYED TO FURTHER INVESTIGATE THE PHYSIOLOGIC CONSEQUENCES OF METTL3-MEDIATED M6A ALTERATION ON EMS. RESULTS: OUR DATA SHOW THAT DECREASED METTL3 EXPRESSION SIGNIFICANTLY DOWNREGULATES M6A RNA METHYLATION LEVELS IN ESCS. SILENCING M6A MODIFICATIONS MEDIATED BY METTL3 ACCELERATES ESCS VIABILITY, PROLIFERATION, MIGRATION, AND INVASION IN VITRO. THE M6A READER PROTEIN YTHDF2 BINDS TO M6A MODIFICATIONS TO INDUCE THE DEGRADATION OF SIRT1 MRNA. SIRT1/FOXO3A SIGNALLING PATHWAY ACTIVATION IS SUBSEQUENTLY INHIBITED, PROMOTING THE CELLULAR SENESCENCE OF ESCS AND INHIBITING THE ECTOPIC IMPLANTATION OF ESCS IN VITRO AND IN VIVO. CONCLUSIONS: OUR FINDINGS DEMONSTRATE THAT METTL3-MEDIATED M6A METHYLATION EPIGENETICALLY REGULATES THE ECTOPIC IMPLANTATION OF ESCS, RESULTING IN THE PROGRESSION OF ENDOMETRIOSIS. OUR STUDY ESTABLISHES METTL3-YTHDF2-SIRT1/FOXO3A AS A CRITICAL AXIS AND POTENTIAL MECHANISM IN ENDOMETRIOSIS.	2023	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
14  2634  37 EPIGENOME-WIDE DNA METHYLATION PROFILING OF CONDITIONED PAIN MODULATION IN INDIVIDUALS WITH NON-SPECIFIC CHRONIC LOW BACK PAIN. BACKGROUND: THE PATHOANATOMIC CAUSE OF CHRONIC LOW BACK PAIN (CLBP) CANNOT BE IDENTIFIED FOR UP TO 90% OF INDIVIDUALS. HOWEVER, DYSFUNCTIONAL PROCESSING OF ENDOGENOUS NOCICEPTIVE INPUT, MEASURED AS CONDITIONED PAIN MODULATION (CPM), HAS BEEN ASSOCIATED WITH CLBP AND MAY INVOLVE CHANGES IN NEURONAL GENE EXPRESSION. EPIGENETIC-INDUCED CHANGES SUCH AS DNA METHYLATION (DNAM) HAVE BEEN ASSOCIATED WITH CLBP. METHODS: IN THE PRESENT STUDY, THE RELATIONSHIP BETWEEN CPM AND DNAM CHANGES IN A SAMPLE OF COMMUNITY-DWELLING ADULTS WITH NONSPECIFIC CLBP (N = 48) AND PAIN-FREE CONTROLS (PFC; N = 50) WAS EXAMINED USING REDUCED REPRESENTATION BISULFITE SEQUENCING. GENE ONTOLOGY (GO) TERM ENRICHMENT AND KYOTO ENCYCLOPEDIA OF GENES AND GENOMES (KEGG) PATHWAY ANALYSIS WERE APPLIED TO IDENTIFY KEY PATHWAYS INVOLVED IN EFFICIENT VERSUS DEFICIENT CPM. RESULTS: BASED ON CPM EFFICIENCY, WE IDENTIFIED 6006 AND 18,305 DIFFERENTIALLY METHYLATED CPG SITES (DMCS) WITH Q VALUES < 0.01 AMONG INDIVIDUALS WITH CLBP AND PFCS, RESPECTIVELY. MOST OF THE DMCS WERE HYPOMETHYLATED AND ANNOTATED TO GENES OF RELEVANCE TO PAIN, INCLUDING OPRM1, ADRB2, CACNA2D3, GNA12, LPL, NAXD, AND ASPHD1. IN BOTH CLBP AND PFC GROUPS, THE DMCS ANNOTATED GENES ENRICHED MANY GO TERMS RELEVANT TO PAIN PROCESSING, INCLUDING TRANSCRIPTION REGULATION BY RNA POLYMERASE II, NERVOUS SYSTEM DEVELOPMENT, GENERATION OF NEURONS, NEURON DIFFERENTIATION, AND NEUROGENESIS. BOTH GROUPS ALSO ENRICHED THE PATHWAYS INVOLVED IN RAP1-SIGNALING, CANCER, AND DOPAMINERGIC NEUROGENESIS. HOWEVER, MAPK-RAS SIGNALING PATHWAYS WERE ENRICHED IN THE CLBP, NOT THE PFC GROUP. CONCLUSIONS: THIS IS THE FIRST STUDY TO INVESTIGATE THE GENOME-SCALE DNA METHYLATION PROFILES OF CPM PHENOTYPE IN ADULTS WITH CLBP AND PFCS. BASED ON CPM EFFICIENCY, FEWER DMC ENRICHMENT PATHWAYS WERE UNIQUE TO THE CLBP THAN THE PFCS GROUP. OUR RESULTS SUGGEST THAT EPIGENETICALLY INDUCED MODIFICATION OF NEURONAL DEVELOPMENT/DIFFERENTIATION PATHWAYS MAY AFFECT CPM EFFICIENCY, SUGGESTING NOVEL POTENTIAL THERAPEUTIC TARGETS FOR CENTRAL SENSITIZATION. HOWEVER, CPM EFFICIENCY AND THE EXPERIENCE OF NONSPECIFIC CLBP MAY BE INDEPENDENT. FURTHER MECHANISTIC STUDIES ARE REQUIRED TO CONFIRM THE RELATIONSHIP BETWEEN CPM, CENTRAL SENSITIZATION, AND NONSPECIFIC CLBP.	2022	
                                                                                                                                                                                                                                                                                                                                                                                                                         
15  5668  35 SFRP1 EXPRESSION REGULATES WNT SIGNALING IN CHRONIC MYELOID LEUKEMIA K562 CELLS. BACKGROUND: WNT SIGNALING CASCADES PLAY IMPORTANT ROLES IN CELL FATE DECISIONS AND THEIR DEREGULATION HAS BEEN DOCUMENTED IN MANY DISEASES, INCLUDING MALIGNANT TUMORS AND LEUKEMIA. ONE MECHANISM OF ABERRANT WNT SIGNALING IS THE SILENCING OF WNT INHIBITORS THROUGH EPIGENETIC MECHANISMS. THE SFRPS ARE ONE OF THE MOST STUDIED WNT INHIBITORS; AND THE SFRP1 LOSS IS KNOWN IN MANY HEMATOLOGICAL MALIGNANCIES. THEREFORE, WE AIMED TO COMPARE THE EXPRESSION OF WNT RELATED GENES IN THE PRESENCE AND ABSENCE OF SFRP1 IN A CHRONIC MYELOID LEUKEMIA (CML) CELL LINE. OBJECTIVE: IT IS IMPORTANT TO UNDERSTAND HOW SFRP1 AND SFRP1 PERFORM THEIR EFFECTS ON CML TO DESIGN NEW AGENTS AND STRATEGIES FOR RESISTANT AND ADVANCED FORMS OF CML. MATERIALS AND METHODS: WE USED K562 CELLS, WHICH NORMALLY DO NOT EXPRESS SFRP1 AND ITS SFRP1 EXPRESSING SUBCLONE K562S. TOTAL RNA WAS ISOLATED FROM K562 AND K562S CELL LINES AND CONVERTED TO CDNA. PCR ARRAY EXPERIMENTS WERE PERFORMED USING HUMAN WNT SIGNALING PATHWAY PLUS RT2 PROFILER KIT. WNT SIGNALING PATHWAY ACTIVATION WAS STUDIED BY WESTERN BLOT FOR DOWNSTREAM SIGNALING TARGETS. RESULTS: THE WNT3, LRP6, PRICKLE1 AND BTRC EXPRESSIONS WERE SIGNIFICANTLY DECREASED IN THE PRESENCE OF SFRP1; WHILE WNT5B INCREASED. THE SFRP1 EXPRESSION INHIBITED STABILIZATION OF TOTAL BETA-CATENIN PROTEIN AND DOWNSTREAM EFFECTOR PHOSPHORYLATION OF NONCANONICAL WNT/PCP SIGNALING; WHEREAS CA2+/PKC SIGNALING REMAINED ACTIVE. CONCLUSION: THE RESULTS SUGGEST THAT SFRP1 COULD BE A PROMISING THERAPEUTIC ANTICANCER AGENT. DEFINING THESE PATHWAY INTERACTIONS IS CRUCIAL FOR DESIGNING NEW AGENTS RESISTANT AND ADVANCED FORMS OF CML.	2022	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
16  1022  30 CIRCULAR RNA HSA_CIRC_0098181 INHIBITS METASTASIS IN HEPATOCELLULAR CARCINOMA BY ACTIVATING THE HIPPO SIGNALING PATHWAY VIA INTERACTION WITH EEF2. INTRODUCTION AND OBJECTIVES: THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC) IS A MULTI-STEP PROCESS THAT ACCUMULATES GENETIC AND EPIGENETIC ALTERATIONS, INCLUDING CHANGES IN CIRCULAR RNA (CIRCRNA). THIS STUDY AIMED TO UNDERSTAND THE ALTERATIONS IN CIRCRNA EXPRESSION IN HCC DEVELOPMENT AND METASTASIS AND TO EXPLORE THE BIOLOGICAL FUNCTIONS OF CIRCRNA. MATERIALS AND METHODS: TEN PAIRS OF ADJACENT CHRONIC HEPATITIS TISSUES AND HCC TISSUES FROM PATIENTS WITHOUT VENOUS METASTASES, AND TEN HCC TISSUES FROM PATIENTS WITH VENOUS METASTASES WERE ANALYZED USING HUMAN CIRCRNA MICROARRAYS. DIFFERENTIALLY EXPRESSED CIRCRNAS WERE THEN VALIDATED BY QUANTITATIVE REAL-TIME PCR. IN VITRO AND IN VIVO ASSAYS WERE PERFORMED TO ASSESS THE ROLES OF THE CIRCRNA IN HCC PROGRESSION. RNA PULL-DOWN ASSAY, MASS SPECTROMETRY ANALYSIS, AND RNA-BINDING PROTEIN IMMUNOPRECIPITATION WERE CONDUCTED TO EXPLORE THE PROTEIN PARTNERS OF THE CIRCRNA. RESULTS: CIRCRNA MICROARRAYS REVEALED THAT THE EXPRESSION PATTERNS OF CIRCRNAS ACROSS THE THREE GROUPS WERE SIGNIFICANTLY DIFFERENT. AMONG THESE, HSA_CIRC_0098181 WAS VALIDATED TO BE LOWLY EXPRESSED AND ASSOCIATED WITH POOR PROGNOSIS IN HCC PATIENTS. ECTOPIC EXPRESSION OF HSA_CIRC_0098181 DELAYED HCC METASTASIS IN VITRO AND IN VIVO. MECHANISTICALLY, HSA_CIRC_0098181 SEQUESTERED EUKARYOTIC TRANSLATION ELONGATION FACTOR 2 (EEF2) AND DISSOCIATED EEF2 FROM FILAMENTOUS ACTIN (F-ACTIN) TO PREVENT F-ACTIN FORMATION, WHICH BLOCKED ACTIVATION OF THE HIPPO SIGNALING PATHWAY. IN ADDITION, THE RNA BINDING PROTEIN QUAKING-5 BOUND DIRECTLY TO HSA_CIRC_0098181 AND INDUCED ITS BIOGENESIS. CONCLUSIONS: OUR STUDY REVEALS CHANGES IN CIRCRNA EXPRESSION FROM CHRONIC HEPATITIS, PRIMARY HCC, TO METASTATIC HCC. FURTHER, THE QKI5-HSA_CIRC_0098181-EEF2-HIPPO SIGNALING PATHWAY EXERTS A REGULATORY ROLE IN HCC.	2023	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
17  5458  31 RESEARCH ON EPIGENETIC MECHANISM OF SFRP2 IN ADVANCED CHRONIC MYELOID LEUKEMIA. SECRETED FRIZZLED-RELATED PROTEIN 2 (SFRP2) HAS BEEN REPORTED TO ACT AS A TUMOR SUPPRESSORS. THIS STUDY AIMS TO DETECT THE BIOLOGICAL ROLE OF SFRP2 IN ADVANCED CHRONIC MYELOID LEUKEMIA (CML). IN THIS STUDY WE EXAMINED BONE MARROW SAMPLES FROM 45 CML PATIENTS AND 10 HEALTHY DONORS. K562 AND KCL22 CELLS WERE CULTURED AND TREATED WITH DEMETHYLATION DRUG AND HISTONE DEACETYLASE INHIBITOR (HDACI). KCL22 AND K562 CELLS WERE TRANSFECTED WITH LENTIVIRAL VECTOR (LV)-SFRP2, LV-CONTROL. THE CELLS WERE THEN SUBJECTED TO PROLIFERATION AND APOPTOSIS ASSAYS, REAL TIME POLYMERASE CHAIN REACTION (PCR), METHYLATION-SPECIFIC PCR (MSP), WESTERN BLOTTING, CO-IMMUNOPRECIPITATION (COIP) AND CHROMATIN IMMUNOPRECIPITATION (CHIP), WE FOUND THAT SFRP2 WAS DOWN-REGULATED IN THE ACCELERATED AND BLAST PHASE OF CML, WHEREAS, THE LEVELS OF WNT1, WNT3 AND WNT5A WERE UP-REGULATED IN THE ACCELERATED AND BLAST PHASE OF CML. OVEREXPRESSION SFRP2 INHIBITED PROLIFERATION, PROMOTED APOPTOSIS AND ACTIVATED THE WNT PATHWAY. COIP-MS RESULTS SHOWED THAT SFRP2 INTERACTED WITH WNT1 AND WNT5A. CHIP-SEQ RESULT INDICATED THAT THE PROMOTER OF H3K4ME3 AND H3K27ME3 WERE ABLE TO INTERACT WITH SFRP2. IN CONCLUSION, OUR FINDINGS DEMONSTRATED THE SFRP2 ACT AS A POTENTIAL THERAPEUTIC TARGET FOR ADVANCED CML. FURTHERMORE, OUR RESULTS SUPPORT THE USE OF DEMETHYLATION DRUGS AND HDACI AS A POTENTIAL CML TREATMENT STRATEGY.	2018	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
18  6235  26 THE M(6)A DEMETHYLASE FTO PROMOTES RENAL EPITHELIAL-MESENCHYMAL TRANSITION BY REDUCING THE M(6)A MODIFICATION OF LNCRNA GAS5. BACKGROUND: RENAL INTERSTITIAL FIBROSIS (RIF) IS THE MAIN PATHOLOGICAL CHANGE OF A VARIETY OF CHRONIC KIDNEY DISEASES (CKD). EPIGENETIC MODIFICATIONS OF FIBROSIS-PRONE GENES REGULATE RIF PROGRESSION. THIS STUDY AIMED TO INVESTIGATE LONG NON-CODING RNA (LNCRNA) N6-METHYLADENOSINE (M(6)A) MODIFICATION AND ITS ROLE IN REGULATING RIF PROGRESSION. METHODS: UNILATERAL URETERAL OCCLUSION (UUO) WAS EMPLOYED TO CONSTRUCT THE RIF IN VIVO MODEL; AND TGF-BETA1-TREATED HK-2 AND HKC-8 CELLS WERE USED FOR IN VITRO EXPERIMENTS. THE MRNA AND PROTEIN EXPRESSIONS WERE ASSESSED USING QRT-PCR AND WESTERN BLOT. THE PROLIFERATION AND MIGRATION WERE EVALUATED BY EDU ASSAY AND TRANSWELL ASSAY, RESPECTIVELY. IN ADDITION, LEVELS OF INFLAMMATORY CYTOKINES WERE DETERMINED BY ELISA ASSAY AND QRT-PCR. MOREOVER, LNCRNA GAS5 M(6)A LEVEL WAS DETECTED USING ME-RIP ASSAY. HE AND MASSON STAINING WERE EMPLOYED TO EVALUATE FIBROTIC LESIONS OF THE KIDNEY. RESULTS: FTO EXPRESSION WAS ELEVATED IN HK-2 AND HKC-8 CELLS AFTER TGF-BETA1 TREATMENT AND MOUSE KIDNEY TISSUE FOLLOWING UUO, AND LNCRNA GAS5 WAS DOWNREGULATED. LNCRNA GAS5 OVEREXPRESSION OR FTO SILENCING SUPPRESSED TGF-BETA1-INDUCED THE INCREASE OF EMT-RELATED PROTEINS (VIMENTIN, SNAIL AND N-CADHERIN) AND INFLAMMATORY CYTOKINES (IL-6, IL-1BETA AND TNF-ALPHA) LEVELS IN HK-2 CELLS. FTO SUPPRESSED LNCRNA GAS5 EXPRESSION BY REDUCING THE M6A MODIFICATION OF LNCRNA GAS5. ADDITIONALLY, FTO KNOCKDOWN COULD SUPPRESS EMT PROCESS AND INFLAMMATION RESPONSE INDUCED BY TGF-BETA1 AND UUO IN VITRO AND IN VIVO. AS EXPECTED, FTO KNOCKDOWN ABROGATED THE PROMOTION EFFECTS OF LNCRNA GAS5 SILENCING ON TGF-BETA1-INDUCED EMT PROCESS AND INFLAMMATION RESPONSE IN HK-2 AND HKC-8 CELLS. CONCLUSION: FTO PROMOTED EMT PROCESS AND INFLAMMATION RESPONSE THROUGH REDUCING THE M(6)A MODIFICATION OF LNCRNA GAS5.	2022	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
19  4005  21 LOSS OF THE TUMOR SUPPRESSOR BAP1 CAUSES MYELOID TRANSFORMATION. DE-UBIQUITINATING ENZYME BAP1 IS MUTATED IN A HEREDITARY CANCER SYNDROME WITH INCREASED RISK OF MESOTHELIOMA AND UVEAL MELANOMA. SOMATIC BAP1 MUTATIONS OCCUR IN VARIOUS MALIGNANCIES. WE SHOW THAT MOUSE BAP1 GENE DELETION IS LETHAL DURING EMBRYOGENESIS, BUT SYSTEMIC OR HEMATOPOIETIC-RESTRICTED DELETION IN ADULTS RECAPITULATES FEATURES OF HUMAN MYELODYSPLASTIC SYNDROME (MDS). KNOCKIN MICE EXPRESSING BAP1 WITH A 3XFLAG TAG REVEALED THAT BAP1 INTERACTS WITH HOST CELL FACTOR-1 (HCF-1), O-LINKED N-ACETYLGLUCOSAMINE TRANSFERASE (OGT), AND THE POLYCOMB GROUP PROTEINS ASXL1 AND ASXL2 IN VIVO. OGT AND HCF-1 LEVELS WERE DECREASED BY BAP1 DELETION, INDICATING A CRITICAL ROLE FOR BAP1 IN STABILIZING THESE EPIGENETIC REGULATORS. HUMAN ASXL1 IS MUTATED FREQUENTLY IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) SO AN ASXL/BAP1 COMPLEX MAY SUPPRESS CMML. A BAP1 CATALYTIC MUTATION FOUND IN A MDS PATIENT IMPLIES THAT BAP1 LOSS OF FUNCTION HAS SIMILAR CONSEQUENCES IN MICE AND HUMANS.	2012	
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
20  5526  18 RNA EDITING IN MESOTHELIOMA: A LOOK FORWARD. RNA EDITING IS A POST-TRANSCRIPTIONAL PROCESS INCREASING TRANSCRIPT DIVERSITY, THEREBY REGULATING DIFFERENT BIOLOGICAL PROCESSES. WE RECENTLY OBSERVED THAT MUTATIONS RESULTING FROM RNA EDITING DUE TO HYDROLYTIC DEAMINATION OF ADENOSINE INCREASE DURING THE DEVELOPMENT OF MESOTHELIOMA, A RARE CANCER LINKED TO CHRONIC EXPOSURE TO ASBESTOS. THIS REVIEW GATHERS INFORMATION FROM THE PUBLISHED LITERATURE AND PUBLIC DATA MINING TO EXPLORE SEVERAL ASPECTS OF RNA EDITING AND THEIR POSSIBLE IMPLICATIONS FOR CANCER GROWTH AND THERAPY. WE ADDRESS POSSIBLE LINKS BETWEEN RNA EDITING AND PARTICULAR TYPES OF MESOTHELIOMA GENETIC AND EPIGENETIC ALTERATIONS AND DISCUSS THE RELEVANCE OF AN EDITED SUBSTRATE IN THE CONTEXT OF CURRENT CHEMOTHERAPY OR IMMUNOTHERAPY.	2020